Manufacture of peripheral DES requires development of process technologies to accommodate their geometrical and biomechanical specifics. In this study, a spray-coating process for peripheral DES coatings was developed. Peripheralsize, self-expanding nickel titanium stents (7.0 x 40 mm) were coated with the biodegradable polymer poly(L-lactide) (PLLA) incorporated with the immunosuppressant sirolimus (SIR) in a ratio of 82.5/17.5 % w/w. Coating mass was 3400 µg. A parameter study was conducted to assess optimum coating parameters. The coated DES were evaluated for coating morphology, thickness, and integrity. Drug release behavior was assessed by HPLC. SEM evaluation confirmed a smooth, defect-free PLLA/SIR coating with complete strut coverage. A coating thickness of 5.5 ± 0.4 µm was determined by CLSM. SIR release was traced over up to 430 h, exhibiting an initial burst over 30 h, followed by a steady, retarded drug release. Altogether, the results indicate the technical feasibility of self-expanding, peripheral DES.
Introduction
Drug-eluting stents (DES) for the peripheral vasculature are currently evolving into a potential new field of DES application. Manufacture of drugs coatings for such peripheral DES requires development of process technologies to accommodate their geometrical and biomechanical specifics. In particular, larger size and size range (d = 4 -10 mm, l = 20 -200 mm), as well as self-expanding properties of these stents have to be considered. In this study, a spray-coating process for the manufacture of second generation biodegradable DES coatings [1] was developed for a peripheral self-expanding stent. Prototypes were assessed regarding coating quality and drug release behavior.
Methods
Peripheral-size, self-expanding nickel titanium (nitinol) stents (nominal dimensions: 7.0 x 40 mm, surface area: 455 mm²) were coated with a coating mass of 3400 µg in a Image 1 Schematic of implemented the 2-step semiautomatic spray-coating process modified spray-coating process based on 2-component jet atomization technology according to [2] . Image 1 shows the implemented semi-automatic spray-coating process.
The biodegradable polymer poly(L-lactide) (PLLA) incorporated with the immunosuppressant sirolimus (SIR) in a ratio of 82.5/17.5 % w/w was used as coating compound, resulting in a SIR surface concentration of 1.3 µg/mm². After coating, the DES prototypes were dried at 80°C for 13 h. A parameter study was conducted to assess optimum coating parameters. The coated DES were evaluated for coating morphology, thickness, and integrity by SEM and CLSM. Coating thickness was evaluated in 5 longitudinally equidistant planes. Drug release behavior was assessed by HPLC.
Results
A suitable parameter window (nozzle aperture = 0.5 mm, nozzle distance = 30 mm, spraying pressure = 0.2 bar, process time = 1400 s) was identified for efficient manufacture of peripheral DES. Mean mass loss during the drying cycle was 16 %. SEM evaluation confirmed a smooth, defect-free PLLA/SIR coating with complete strut coverage. Image 2 shows the coating morphology in comparison to an uncoated specimen. A coating thickness of 5.5 ± 0.4 µm, and a roughness index (Ra) of less than 0.3 µm were determined by CLSM, as illustrated in Image 3. Image 4 shows the determined longitudinal coating thickness distribution over the entire stent length. SIR release was traced over up to 430 h. The drug release pattern showed an initial burst over 30 h, followed by a steady, retarded SIR release, see Image 5.
Image 2 Uncoated (A) and PLLA/SIR coated nitinol stent prototypes (B-D)
Image 3 3-D CLSM imaging; representative DES coating surface (bottom right) and underlying nitinol/SiC stent surface (bottom left). The coating thickness and roughness profile (xz-scan) is evaluated along the dashed lines. It is generated from an overlay of line scans in different focal planes. Changes in refractive index result in optical reflexes at the materials interfaces. 
